April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas
Jan 29, 2025, 12:53

Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas

Leo Mascarenhas, Division Chief and Director of Pediatric Hematology and Oncology at Cedars-Sinai Guerin Children, shared an article on LinkedIn:

“Hot of the press!

Some insight into the implications of stopping treatment in young sarcoma patients!”

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.

Authors: Leo Mascarenhas, et al.

Leo Mascarenhas: Elective Discontinuation of Larotrectinib in Pediatric Patients with TRK Fusion Sarcomas